Navigation Links
Ovarian Cancer Prognosis May Depend on Gene Mutations
Date:4/4/2011

MONDAY, April 4 (HealthDay News) -- Ovarian cancer patients with the BRCA2 gene mutation are more likely to survive than those with the BRCA1 mutation or patients without either mutation, a new study finds.

U.S. researchers analyzed 3,531 cases of epithelial ovarian cancer, including 1,178 patients with BRCA1 mutations, 367 with BRCA2 mutations and 1,986 with neither mutation.

Five-year survival rates were 61 percent for those with the BRCA2 mutation, 46 percent for those with the BRCA1 mutation and 36 percent for those with neither mutation, the investigators found.

The study is to be presented Monday at the annual meeting of the American Association for Cancer Research, in Orlando, Fla. The research is considered preliminary until it is published in a peer-reviewed journal.

"There was some previous evidence that women with ovarian cancer who have mutations in the BRCA genes show improved survival compared to non-mutation carriers. Our study clearly shows that this survival difference is real. We also provide the first solid evidence that BRCA1 and BRCA2 mutations don't have the same impact on ovarian cancer survival," Kelly Bolton, a fellow at the U.S. National Cancer Institute, said in an AACR news release.

Further research is needed to find out why BRCA2 mutations are associated with better survival than BRCA1 mutations or no mutations. The mutations may affect a patient's response to chemotherapy, Bolton suggested.

About 1 in 400 to 1 in 800 women are born with either the BRCA1 or BRCA2 mutations, which increase the risk of ovarian and breast cancer. About 5 percent of ovarian cancer patients have BRCA1 or BRCA2 mutations.

More information

The American Cancer Society has more about ovarian cancer.

-- Robert Preidt

SOURCE: American Association for Cancer Research, news release, April 4, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Philanthropic pledge triples funds for TGen ovarian cancer research
2. Ohio State study: Targeted ovarian cancer therapy not cost-effective
3. GPs take more than a month to record ovarian cancer diagnosis in one in 10 cases
4. Nearly 25% of Women With Early Ovarian Cancer Not Given Recommended Biopsies
5. New clinical trial to determine ovarian cancer risks in African-American women
6. Ovarian Cyst Syndrome May Raise Health Risks from Plastics Chemical
7. UH biochemist works to revolutionize ovarian cancer treatment
8. Ovarian cancer advances when genes are silenced
9. Few Lives Saved by Ovarian Cancer Screening: Study
10. Biological diversity of ovarian cancer lessens value of screening
11. Researchers map the way to personalised treatment for ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ovarian Cancer Prognosis May Depend on Gene Mutations
(Date:3/27/2017)... , ... March 27, 2017 , ... ... organization behind the New England Journal of Medicine and NEJM Journal Watch, announces ... Pediatrics Board Review was created by a panel of pediatricians from leading medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, ... packaged with the April edition of American Veterinarian™. , “We look ...
(Date:3/27/2017)... ... 2017 , ... Advantexe Learning Solutions , a global ... new research study, The Business Readiness Report. The report explores the correlation between ... actual success of achieving individual and company goals. , There are many ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association ... chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. ... “Increasingly, supply chain and value analysis professionals have a ‘seat at the table’ ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office ... First National Capital has added 10 new sales professionals over the past 6 months ... by 15 additional new hires over the course of 2017. , “This new ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical ... Cambridge academic scientists through ... Milner Therapeutics Institute today announces Elysium Health as a partner ... investment for collaborative projects with academic researchers in ... the first major research investment outside the U.S. for the ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
(Date:3/27/2017)... VANCOUVER, British Columbia , March 27, 2017 /PRNewswire/ ... of Directors has appointed William "Bill" Dubiel as President ... Dubiel was also elected to the Board of Directors ... serve as the Executive Chairman of LightIntegra. ... become LightIntegra,s next President and Chief Executive Officer. We,ve ...
Breaking Medicine Technology: